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Abstract
Hepatitis C virus (HCV) shows a great geographical diversity reflected in the high number of circulating genotypes and
subtypes. The response to HCV treatment is genotype specific, with the predominant genotype 1 showing the lowest rate of
sustained virological response. Virally encoded enzymes are candidate targets for intervention. In particular, promising
antiviralmoleculesarebeing developedtotargetthe viralNS3/4Aprotease and NS5B polymerase.Mostofthestudieswiththe
NS5B polymerase have been done with genotypes 1b and 2a, whilst information about other genotypes is scarce. Here, we
have characterized the de novo activity of NS5B from genotypes 1 to 5, with emphasis on conditions for optimum activity and
kinetic constants. Polymerase cooperativity was determined by calculating the Hill coefficient and oligomerization through a
new FRET-based method. The Vmax/Km ratios were statistically different between genotype 1 and the other genotypes
(p,0.001), mainly due to differences in Vmax values, but differences in the Hill coefficient and NS5B oligomerization were
noted. Analysis of sequence changes among the studied polymerases and crystal structures show the aF helix as a structural
component probably involved in NS5B-NS5B interactions. The viability of the interaction of aFa n daT helixes was confirmed
by docking studies and calculation of electrostatic surface potentials for genotype 1 and point mutants corresponding to
mutations from different genotypes. Results presented in this study reveal the existence of genotypic differences in NS5B de
novo activityandoligomerization. Furthermore,theseresultsallowustodefinetworegions,oneconsisting ofresiduesGlu128,
Asp129, and Glu248, and the other consisting of residues of aT helix possibly involved in NS5B-NS5B interactions.
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Introduction
The hepatitis C virus (HCV) is a positive-strand RNA ((+)RNA)
virus with a high-titer and error-prone replication rate leading to
the generation of viral populations in which mixtures of almost
infinite different variants may coexist [1,2,3]. HCV infection is
widespread worldwide, showing geographical differences in terms
of genetic identity with six well defined genotypes [4–6]. Important
biological and antigenic differences exist between variants, and
different genotypes respond differently to treatment [7]. The goal
of HCV treatment is to achieve a sustained virological response
(SVR) defined as the absence of HCV viral load for at least six
months after the end of the treatment. About 80% of patients
infected with genotypes 2, 3 and 5 achieve SVR after treatment
with pegylated-interferon (PEG-IFN) plus ribavirin, whereas the
rate of SVR is roughly 50% among those with genotype 1 and it is
somewhat intermediate for genotypes 4 and 6 [8].
HCV replicates its positive sense genome through an RNA
intermediate of negative sense [9]. The NS5B protein is responsible
for the synthesis of the (+) strand progeny via a (2) strand
intermediate through an RNA-dependent RNA-polymerase
(RdRp) activity [10,11]. In vitro RNA synthesis by NS5B may be
induced in the presence of a template-primer or initiated de novo.
However, RNA synthesis in vivo occurs by a de novo mechanism
[12,13]. Manganese has been proposed as the preferred cation for
HCV NS5B for the de novo initiation step [12,14]. Most
biochemical and biophysical studies of NS5B have been done with
genotype 1b and have disregarded the NS5B polymerase activity of
viruses from different genotypes. The biochemical properties of
NS5B of other genotypes have been described in the context of
NS5B inhibitor studies [15–19] without a comprehensive analysis of
the polymerase activities of all 6 genotypes [20].
Similarly to other (+)RNA viruses, HCV replicates its genome
in, so called, replication complexes (RC), where viral and cellular
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18515proteins co-localize. In HCV RC, a large excess of each HCV
non-structural protein respect to (+) and (2) strand HCV RNA has
been observed [21], suggesting extensive protein-protein interac-
tions and molecular crowding phenomena. HCV NS5B interacts
with itself, affecting RNA synthesis activity in a cooperative way
[22]. This interaction has been proposed as the target for some of
the non-nucleoside inhibitors directed against the NS5B protein
[23–26].
Here, we have cloned, over-expressed, purified and evaluated
NS5B polymerases from different HCV genotypes. Reaction
conditions for RdRp activity in a de novo initiation assay, and
cooperativity have been analyzed for proteins derived for
genotypes 1 to 5. Also, we have analyzed NS5B-NS5B interactions
in vitro by a fluorescence resonance energy transfer (FRET)-based
method using HCV polymerases fused with GFP derivatives.
Finally, we have performed docking simulations. Our results
together with primary amino acid sequences and structural data
deposited at the Protein Data Bank have allowed us to define
residues probably involved in NS5B-NS5B interactions.
Materials and Methods
NS5BD21 polymerases, fusion proteins and plasmids
construction
Plasmids containing the gene coding regions of HCV NS5B of
genotypes 1 to 5 were constructed by molecular cloning. NS5B
polymerases were amplified as deletion mutants of the 21 amino
acids of their C-terminal end (NS5BD21) to avoid the presence of
the highly hydrophobic domain and ensure the solubility of the
enzyme. NS5B from genotypes 1b and 2a were obtained from
plasmids pCVJ4L6S and pJ6CF respectively, kindly provided by
Dr. Jens Bukh (University of Copenhagen). NS5B-coding regions
from HCV genotypes 3, 4, and 5 were obtained as follows. Briefly,
plasma samples from patients infected with HCV of these
genotypes were collected and viral RNA was extracted by using
the QIAamp Viral RNA Mini Kit (Qiagen, Barcelona, Spain)
following the manufacturer instructions. cDNA was synthesized by
amplification with genotype-specific antisense primers (Table S1)
and a mixture of Superscript
TM III Reverse Transcriptase
(Invitrogen, El Prat de Llobregat, Spain) and AMV Reverse
Transcriptase (Promega, Madrid, Spain) as described by Fan et al
[27]. Primers designed to amplify the complete HCV polyprotein
coding region were used in a first round of PCR amplification.
Then, a nested PCR with internal primers designed to amplify the
complete NS5B-coding region was performed and the purified
products were cloned into a high copy vector (pSC-B-amp/kan
from the Strataclone Blunt PCR Cloning kit, Stratagene, Madrid,
Spain), following the manufacturer instructions. DNA of the
resulting D21 mutants from genotypes 1 to 5 flanked by sequences
required for recombination with the Gateway technology
(Invitrogen) and a 6xHis tag at the c-terminal were amplified by
PCR and introduced into the pDEST14 vector (Invitrogen) for
expression in E. coli of the corresponding protein following the
manufacturer instructions.
NS5BD21fromgenotypes1to5werefusedtofluorescentproteins
(FP), either cyan or citrine, as previously described [23]. All PCR
reactions were performed using a high-fidelity polymerase (rTth
DNA Polymerase, XL from Applied Biosystems, Madrid, Spain,
Expand High Fidelity System from Roche,Valencia, Spain, or Pfu
Turbo DNA polymerase from Stratagene). PCR products contain-
ing NS5BD21-FP fusions were cloned into the pDest14 vector by
using the Gateway technology to obtain the final pDest14-
NS5BD21-FP constructs (NS5BD21-cyan and NS5BD21-citrine).
All constructs were verified by DNA sequencing (Macrogen, Korea).
Genotyping and phylogenetic analyses
Genotyping was confirmed by using the sequences obtained
above. Briefly, multiple sequence alignments were carried out
using the CLUSTALX software [28]. Phylogenetic analyses were
performed using the neighbor-joining method included in the
PHYLIP software package [29]. The robustness of the grouping
was determined by bootstrap re-sampling of multiple sequence
alignments (100 sets) with the programs SEQBOOT, DNADIST,
NEIGHBOR, and CONSENSE. The output graphics of the trees
were created with the TREEVIEW software package, version 1.5.
Genotype reference sequences were downloaded from Los Alamos
HCV database [4]. Patient-derived NS5B sequences from genotypes
3, 4 and 5 have been deposited under the GenBank Accession
Numbers HM107694, HM107695 and HM107696 respectively.
Protein over-expression and purification
Proteins of all five genotypes used in this study were over-
expressed and purified as previously reported [23]. Aliquots
showing purest and most concentrated protein were adjusted to
50% glicerol and stored at 280uC. All purification processes were
followed by SDS-PAGE and Coomassie blue staining and
quantified by Bradford protein assay and SDS-PAGE gel imaging.
Western blots were performed by standard procedures using a-
NS5B (Abcam, Cambridge, UK) as the primary antibody.
Polymerase activity assay and determination of kinetic
constants
De novo RdRp activity of purified NS5BD21s was examined by
incorporation of radiolabeled GMP on homopolymeric (polyC)
template (average length of 300 residues). The reaction was
performed, except when indicated, in polymerase buffer (20 mM
MOPS pH 7.25, 66 mM NaCl, 5 mM MnCl2, and 40 ng/mlo f
polyC), in the presence of 125 mM GTP, and 0.5 mCi of
a[
32P]GTP (3000 Ci/mmol, PerkinElmer). Reactions were initi-
ated by the addition of 600 nM purified NS5B and incubated at
25uC. The nominal input concentration of NS5BD21 was
600 nM, however, it has been established that only a small
fraction (,1%) of NS5BD21 enzyme purified from bacteria is
catalytically competent in vitro [30]. Aliquots were withdrawn over
time and reactions were stopped by adding 150 mM EDTA.
Reaction products were transferred onto DE81 paper membrane
(Whatman International Ltd, Barcelona, Spain). DE81 filter
papers were then washed twice with 9 ml of 0.2 mM Na2HPO4,
once with 9 ml of H2O and once with 3 ml of absolute ethanol,
and dried for 15 min at 55uC. The radioactivity bound to the filter
was determined using liquid scintillation counting (LS6500,
Beckman Coulter). Polymerase activity of NS5BD21-fluorescence
proteins was determined using LE19 RNA as template, as
previously described [14].
The homopolymeric (polyC) template (average length of 300
residues) was used to analyze the kinetic constants Vmax and Km
for GTP. Briefly, 0.5 mCi of a[
32P]GTP (3000Ci/mmol, Perki-
nElmer) and 600 nM of purified NS5B were added to polymerase
buffer, and the reactions were started by addition of GTP (6.25,
12.5, 25, 50, 100, 200, 300, 500, and 1000 mM), and incubated at
25uC for 15 minutes. GMP incorporation was measured by liquid
scintillation counting as described above. Similar procedures were
done to calculate the kinetic parameters for the template (polyC).
No attempts were made to titrate the active site concentration of
NS5B preparations. Therefore, maximum velocity values (Vmax)
related to total enzyme concentration are reported instead of kcat
values. To ensure that protein preparations were properly folded
and they were active for RNA binding, electro-mobility shift assay
HCV RdRP De Novo Activity and Oligomerization
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performed as previously described [23].The dependence of Vi on
NTP or polyC concentrations are described by a hyperbolic
equation from which we can calculate Vmax and Km, the maximal
velocity and the affinity constant (for NTP or polyC) by NS5B,
respectively. Vmax and Km were determined from curve-fitting
using GraphPad Prism (GraphPad Software Inc).
For calculation of the Hill coefficient, polymerase reactions were
performed in polymerase buffer in the presence of 125 mM GTP,
and 0.5 mCi of a[
32P]GTP (3000Ci/mmol, PerkinElmer). The
polymerase concentration was increased from 37.5 nM to 1.5 mM.
Specific activity was fitted to a sigmoidal curve using the equation
log(v/[Vmax - v])=h log[E] - log K, described by Copeland [31],
where v is the velocity at a given enzyme concentration [E] and h
is the Hill coefficient. h values above 1 indicate positive
cooperative RNA synthesis.
Fluorescence spectroscopic and FRET analyses
Fluorescence spectroscopic analyses for each NS5BD21-FP
individually (50 nM final concentration) as well as FRET analyses
f o rm i x t u r e so fN S 5 B D21-cyan and NS5BD21-citrine of each
genotype (50 nM final concentration of each protein) were
performed as previously described [23]. For fluorescence spectro-
scopic analyses of NS5BD21-cyan, the excitation wavelength (lex)
was set at 432 nm (excitation wavelength for cyan) and the
fluorescence emission spectra were obtained from 460 to 600 nm.
Figure 1. Amino acid sequences of the isolates used in this study. Alignment of the predicted amino acid sequences (D21) of the NS5B
proteins used in this study and the consensus sequences corresponding to subtypes 1b, 2a, 3a and 5a. As only 1 sequence for subtype 4d was
present in the http://hcv.lanl.gov/the consensus for NS5BD-4d corresponds to the whole genotype 4. Only differences with a general consensus
sequence are shown. Gray boxes indicate the sequences corresponding to ahelixes C, F, K, L, and N.
doi:10.1371/journal.pone.0018515.g001
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for citrine) and the fluorescenceemission spectrawere obtained from
500 to600 nm.ForFRETanalyses(mixturesofNS5BD21-cyan and
NS5BD21-citrine), lex was set at 432 nm to obtain fluorescence
emission spectra from 460 to 600 nm. Spectra were recorded at
1200 nm/min using a five nm slit and the photomultiplier set at
600 V. If FRET conditions are optimal, then fluorescence increases
at 530 nm (F530 citrine emission, FRET signal), while fluorescence
at 478 nm decreases (F478 primary cyan emission) with an isosbestic
wavelength at ,512 nm. As negative control, we subtracted the
spectra obtained in the presence of NS5BD21-citrine alone because
citrine cross-excites slightly at 432 nm. Finally, the data were used to
calculate a simple ratio of FRET (emission at 530 nm/emission at
478 nm). Fluorescence measurements were obtained in a Hitachi F-
7000 Fluorescence Spectrophotometer.
Electrostatic surface potential
Adaptative Poisson-Boltzmann Solver is a software that
calculates numerical solutions of the Poisson-Boltzmann equation,
describing electrostatic interactions between molecular solutes in
salty, aqueous media. The color coded electrostatic surface
potential for NS5B was drawn using the Adaptive Poisson-
Boltzmann Solver package [32] within PYMOL 1.3 [33] using
2ZKU.pdb as template for building a protein-protein complex. In
silico point mutations in the F helix for the different genotypes
were performed with FoldX [34] and 2ZKU.pdb as template.
Energy minimization for all the structures that were involved in
these studies was done using the FoldX software.
Table 1. Genetic distances.
G1bD21 G2aD21 G3aD21 G4dD21 G5aD21 CON_ _1b CON_ _2a CON_ _3a CON_ _4 CON_ _5a
G1bD21 - 33.50 31.49 29.60 31.81 4.20 33.19 31.07 28.43 31.68
G2aD21 42.21 - 34.10 36.25 31.07 34.00 2.09 34.15 34.02 31.88
G3aD21 41.37 44.14 - 23.07 30.81 32.26 33.25 1.95 23.91 32.77
G4dD21 34.71 42.40 34.75 - 29.02 29.06 34.17 23.58 10.27 31.64
G5aD21 38.80 41.31 39.88 40.30 - 29.44 29.53 30.95 30.74 3.33
CON_1b 5.13 42.81 41.04 34.90 37.71 - 33.63 32.35 29.56 30.19
CON_2a 42.83 4.76 43.77 41.73 42.23 42.91 - 33.37 32.73 30.10
CON_3a 39.39 45.25 3.95 35.40 41.28 39.55 44.88 - 23.50 32.89
CON_4 36.92 41.81 34.49 15.64 38.32 37.22 41.20 34.81 - 32.74
CON_5a 39.61 41.08 41.65 40.26 7.54 38.26 41.89 42.87 39.61 -
Nucleotide (below diagonal) and protein (above diagonal) distance matrix in percentage obtained by the Kimura 2-parameters and the Dayhoff PAM method,
respectively, between the NS5B sequences used in this study and consensus sequences obtained for the 5 major genotypes.
doi:10.1371/journal.pone.0018515.t001
Figure 2. Phylogenetic analysis. Neighbor-joining phylogram of
NS5BD21 from this study (G1, G2, G3, G4 and G5) and the same
reference sequences as in A). A consensus for genotype 6 has also been
included. Bootstrap analysis was performed with 100 repetitions. * =
bootstrap values of 100% showing the divergence of the different
genotypes.
doi:10.1371/journal.pone.0018515.g002
Figure 3. Purification of NS5BD21 proteins by affinity chorma-
tography and cationic exchange. A) Purified proteins after cationic
exchange chromatography (heparin-sepharose column) eluted at
500 mM NaCl and detected with Coomassie blue staining. B) Western
blot detection of HCV NS5B genotypes 1 to 5 with a polyclonal
antibody. Protein molecular weigth markers (in kilodaltons) are shown
on the left.
doi:10.1371/journal.pone.0018515.g003
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The GRAMM-X Protein Docking Web Server v.1.2.0 [35] was
used for docking the NS5B with itself. The output PDB file contains
the desired number of models (between 1 and 300) ranked as the
most probable prediction candidates according to the scoring
function used by the program. The same 2ZKU.pdb acted as
receptor and ligand in this study of oligomerization. We used
positions His502 to Arg508 as receptor residues that might form the
interface with the ligand, and position Asp125 to Asp129 as
potential ligand interface residues. To select a model out of the top
scoring docked complexes reported by GRAMM-X, we calculated
the binding energy on the generated complexes removing
intraclashes (using the strongest van der Waals parameters) with
FoldX [34]. Ionic protein-protein interactions were studied with the
Protein Interaction Calculator (PIC) web server [36].
Results
PCR amplification of NS5B-coding sequences and
genotyping
Viral RNAs from plasma of patients infected with HCV
genotypes 3, 4 and 5 were used as templates for RT-PCRs.
Genotype-derived amino acid sequences corresponding to the
NS5BD21 used in this study (named G1b, G2a, G3a, G4d and
G5a) were aligned together with consensus sequences from each
genotype (named CON_#genotype) (Fig. 1). Amino acid identity
among genotypes was around 75–82%. Nucleotide (Kimura 2-
parameters) and protein (Dayhoff PAM method) distances among
the different NS5B sequences and the consensus for each genotype
are shown in Table 1. We found distances up to 45% and 36% for
nucleotide and amino acid sequences, respectively. Phylogenetic
analyses using reference sequences confirmed the genotype and
subtype of the isolates used in this study (Fig. 2).
Purification of NS5BD21 proteins from different
genotypes
HCV NS5BD21 proteins containing a 6x histidine tag at the C-
terminal were over-expressed and purified to apparent homoge-
neity, as judged by SDS-PAGE and Coomassie blue staining. The
electrophoretic mobility of the purified NS5BD21 proteins was
compatible with their deduced molecular mass (63.2–63.4 kDa),
although with small differences among genotypes (Fig. 3A).
Typical protein yields ranged from 2 to 10 mg. Bands corre-
sponding to NS5BD21for all five genotypes were further identified
by Western blot analyses with a polyclonal antibody directed
against the NS5B from genotype 1b (Fig. 3B). Genotype 5 showed
the weakest band, probably due to sequence changes in the
antibody recognition sites. Fusion proteins (NS5BD21-FPs) for
FRET studies were also purified and the electrophoretic mobility
was also compatible with their deduced molecular mass (90 KDa
approximately, data not shown).
Biochemical properties of NS5BD21 from different
genotypes
The Vmax and Km constants for GTP were calculated for HCV
NS5BD21 polymerases from all 5 genotypes and the results are
shown in Table 2. The affinity of NS5BD21for GTP showed small
differences among genotypes and ranged from almost 100 mMt o
208 mM. However, Vmax values showed great differences among
them. Genotype 1 NS5BD21 showed the highest Vmax which was
4-fold higher than that of genotype 3, almost 7-fold higher than
those of genotypes 2 and 5, and more than 20–fold higher than the
calculated Vmax for NS5BD21 from genotype 4. Therefore, the
Vmax/Km ratio decreased approximately 6-, 7.5- and 8- fold for
genotypes 2, 3 and 5 respectively, and 34-fold for genotype 4 with
respect to genotype 1. In contrast, the template kinetic constants
(polyC in our studies) did not show significant differences among
polymerases from different genotypes, with Km values ranging
from 53 nM to 119 nM (Table 2).
Electro-mobility shift assay experiments for each genotype at
two different protein concentrations were performed as described
in Materials and Methods. We did not find substantial differences
between genotypes (Figure S1A). At the NS5B concentration at
which the RNA polymerase activity was determined (600 nM) the
ratio of protein-bound to free RNA probe was 1.12, 0.59, 0.72,
1.05 and 0.63 for genotypes 1, 2, 3, 4, and 5, respectively (Figure
S1B). The value Vmax/Km was calculated normalized with regard
to this ratio and is also shown (Figure S1C). Results with and
without normalization were very similar and three groups could be
defined, being genotype 1b the most efficient, genotypes 2, 3, and
5 showing an intermediate efficiency, and genotype 4 the less
efficient RNA-polymerase.
Effect of the reaction conditions on polymerase activity
Results for de novo RdRp activity at different conditions of ionic
strength, manganese concentration and pH are shown in Fig. 4A,
B and C, respectively. Reaction curves were normalized fixing the
maximum activity for each protein to 100%. The curves obtained
for each condition showed similar trends among genotypes,
allowing the determination of the optimal conditions for the de
novo RNA polymerase activity. The maximum RdRp activity was
obtained at NaCl concentration below 80 mM, at high Mn
2+
concentration (above 5 mM) and at pH around 7.
Table 2. Kinetic constants and Hill coefficients of HCV NS5B polymerase of different genotypes.
Genotype Kinetic constants Hill coefficient
GTP Template (polyC)
a
Km (mM) Vmax (pmoles/min) Vmax/Km Km (nM)
NS5BD21-1b 117.6624.40 14.361.242 0.122 95.54618.57 2.960.6
NS5BD21-2a 99.44622.96 2.5360.187 0.020 57.52616.96 1.960.3
NS5BD21-3a 208.6640.3 3.2360.316 0.015 118.9622.80 3.860.6
NS5BD21-4d 184.5464.69 0.6660.0594 3.59x10
23 53.24611.39 2.660.2
NS5BD21-5a 134.6641,67 2.1860.215 0.016 65.47625.11 -
aReferred to 59 ends.
doi:10.1371/journal.pone.0018515.t002
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The NS5B polymerases from genotypes 1 to 5 were titrated to
assess the effect of protein concentration on their RNA-polymerase
activity. Titration data are representative of the cooperativity
degree of the polymerases assayed. Data were fitted to a sigmoidal
curve and the Hill coefficient was calculated from it (Figure S2).
All polymerases except that of genotype 5a, showed values above
1, indicating positive cooperativity (Table 2). Values obtained from
genotype 5a did not fit a sigmoidal curve and consequently we
could not calculate its Hill coefficient.
Oligomerization of NS5BD21
Oligomerization of NS5BD21 from genotypes 1 to 5 was
analyzed by FRET. GFP-derived fluorescent proteins cyan and
citrine were fused to genotypes 1 to 5 NS5BD21 proteins to obtain
a pair of fusion proteins per genotype. All these proteins were
active (Figure S3). The genotype-specific oligomerization of the
polymerases described above was analyzed by mixing equimolar
concentrations of the fusion proteins (e.g., NS5BD21-1b-cyan and
NS5BD21-1b-citrine) and exciting the mixtures at 432 nm. The
emission spectra were recorded from 460 to 600 nm. The
observation of a FRET signal (emission at 530 nm) indicated
interaction between both NS5BD21 fusion proteins (Fig. 5A). The
analysis of the obtained spectra (Fig. 5A) allowed the calculation of
a simple ratio of FRET as described in Materials and Methods.
The ratios of FRET obtained for each genotype at 10 mM NaCl
and 4.5 mM Mg(CH3COO)2, and normalized against genotype 1
are shown in Fig. 5B. NS5BD21-1b showed the highest ratio of
FRET, NS5BD21-2a, -3a and -4d showed intermediate values and
the NS5BD21-5a showed the lowest ratio with a value below the
50% of that obtained for genotype 1. We also performed the
FRET experiments under de novo activity conditions (66 mM
NaCl and 5 mM MnCl2), and again, genotype 5 showed the
lowest FRET ratio (Figure 5C). The rest of the proteins showed
FRET ratio values +/2 20% of the 1b genotype (Figure 5C).
In silico approach to the NS5B oligomerization study
Docking studies without selecting putative binding areas
between receptor and ligand gave rise to different complexes that
can be classified according to various criteria, such as calculating
the theoretical binding energy. Based on our oligomerization data
(Fig. 5), previous results [22–24], the abundance of crystallo-
graphic data with inhibitors bound near the aT helix (i.e. 1GX5,
1NHU, 1NHV, 1OS5, 1YVZ, 2BRL, 2D3U, 2D3Z, 2D41,
2DXS, 2GIR, 2HAI, 2HWH, 2HWI, 2I1R, 2JC0, 2O5D,
2WCX, 2WHO, 3CJ0, 3CJ2, 3CJ3, 3CJ4, 3CJ5, 3FRZ and
3HVO), and the comparison of the amino acid sequences among
genotypes (Fig. 6A), allowed us to assume that regions of helixes aF
(112–119) and aT (467–512) could be putative interacting sites
between two NS5B where one was considered as the receptor and
the other was considered as the ligand. Analysis of the electrostatic
surface potential for the aF helix region (Fig. 6B) and aT helix
region (Fig. 6C) showed the complementarities of surface charges.
Moreover, the region corresponding to the aF helix was
engineered for each genotype primary sequence by in silico
mutagenesis using genotype 1b 2ZKU.pdb as a template, as
described in Materials and Methods. The electronegativity
intensity was calculated for each generated surface and the results
are shown in Fig. 6D. Electronegativity was highest for genotype
1b and lowest for genotype 5a, with the following order: G1b .
G2a = G3a = G4d . G5.
We used GRAMM-X [35] for docking one pair of proteins (the
same structure for receptor and ligand in an oligmerization process
using 2ZKU.pdb) to unveil the mode of interaction across the pair
Figure 4. Characterization of the conditions for optimal RNA
synthesis in a ‘‘de novo’’ initiation process by polymerases
from different genotypes. The ability of each polymerase to
synthesize poly-G from [a-
32P]GTP using poly-C template is normalized
with respect to its maximum activity. The effect of the following
conditions was analyzed: A) MnCl2 concentration (metal ion require-
ments), B) pH and, C) NaCl concentration (ionic strength). Reaction
mixtures contained 125 mM GTP and 40 ng/ml of polyC. Reactions in
panel B) were performed with different buffers according to the
selected pH: sodium acetate for pH 5, MES for pH 6, MOPS for pH 7.25,
HEPES for pH 7.75, Tris-HCl for pH 8.25 and CAPS for pH 10. All graphs
show means of at least three independent experiments. Error bars were
lower than 20% in all points and have been removed for clarity.
doi:10.1371/journal.pone.0018515.g004
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the ligand and the region near the aT helix the receptor. The
docking program executes a rigid-body search using Fast Fourier
Transform (FFT) correlation with simplified geometry employing
shape complementarity and hydrophobicity in the scoring function
[37]. Twenty-four out of 200 models were selected and refined
with the FoldX software [34] to eliminate van der Waals clashes,
and the theoretical binding energies were calculated. Ionic
interactions and hydrogen bonding patterns in the complexes of
protein-protein interactions of those refined models were deter-
mined with the Protein Interaction Calculator (PIC) [36]. We
performed a second selection of 6 models with binding energies of
less than or equal to -11 kcal/mol. Results are shown in Table 3
and Fig. 7.
The selected docking models share the involvement of amino
acids of helices aF and aT of two different protein monomers that
form variable number of ion pairs. Interactions of protein-protein
side chain-side chain hydrogen bonds and main chain-side chain
hydrogen bonds are responsible for the theoretically calculated
binding energy. Taking this into account, the best model is the
Model_091, with 211.89 kcal/mol, with up to five ion pairs
between amino acids of each protein chain complex: His475-
Asp129, Arg498-Glu248, Arg501-Glu128, His502-Glu248, Arg505-
Glu248 (Table 3). Hydrophobic protein-protein interactions were
detected in the other four models included in Table 3 except for
Model_091 and Model_034. Anyhow, all models of protein-protein
interactionreportedheremayrepresentallowedinteractionsofNS5B
both in vitro and in vivo.
Discussion
This is the first study where kinetic constants for de novo RdRp
activity for genotypes other than 1 and 2 have been obtained.
Preliminary studies of the NS5B polymerase only detected primer
extension activity [10,11]. However, more recent investigations
have revealed that in vivo HCV RNA is replicated by a de novo
initiation mechanism [12,13]. This discrepancy may be due to the
use of magnesium instead of manganese as the divalent metal and
low concentrations of initiating nucleotide [14,38]. We did not
obtain detectable levels of de novo initiation using magnesium as
divalent cation (data not shown). Thus, we have characterized the
de novo NS5B activity using polyC as template and Mn
2+ as the
divalent cation. The intracellular Mn
2+ concentration is about
100-fold lower than Mg
2+, some authors therefore question the
biological role of Mn
2+ in NS5B replication. However, Mn
2+ has
been proposed as the preferred cation for HCV NS5B in the de
novo initiation [12]. Mn
2+ has also been proposed as the preferred
cation for other flaviviridae RdRps [39]. Furthermore, Mn
2+ has
been shown to be required for W6 RNA polymerase activity,
inducing a flexible structure that favours conformational changes
[40]. On the other hand, it has been described that the apparent
Kd value for the binding of Mg
2+ to the free HCV NS5B enzyme
is 3.1 mM, whereas this is 0.3 mM for Mn
2+ ions [41].
Nevertheless, free metal ion concentrations are tightly regulated
in vivo by special metal ion binding proteins, and their
concentrations may vary considerably in the environment of the
HCV replicative complex [42]. In the case of HCV NS5B, Mn
2+
could be the optimal ion to stabilize the de novo conformation.
Under de novo initiation conditions, Km values for GTP using
NS5B from genotypes 1b and 2a (Table 2) showed comparable
Figure 5. NS5B oligomerization of genotypes 1 to 5. A) Spectra
obtained for a representative FRET experiment. Proteins NS5BD21 fused
to cyan and NS5BD21 fused to citrine were mixed at eqimolar
concentration in FRET buffer. Then, the mixture was excited at
432 nm and spectra were recorded from 460 nm to 600 nm. Two main
peaks were obtained, one corresponding to cyan at approximately
478 nm and the other at approximately 530 nm corresponding to
citrine. FRET ratios were calculated as the ratio of the 530 nm and
478 nm intensities. B) FRET ratios for the interaction of eqimolar
amounts (50 nM each) of NS5BD21-cyan and NS5BD21-citrine for each
genotype are shown. Spectra were obtained in the presence of 10 mM
NaCl and 4.5 mM Mg(CH3COO)2. Values are normalized against the ratio
obtained for NS5BD21-1b and expressed in percentage. Results are the
mean and SEM of twelve independent experiments. C) FRET ratios were
calculated as described above, unless spectra were obtained in the
presence of 66 mM NaCl and 5 mM MnCl2. Ratios are normalized
against the ratio obtained for NS5BD21-1b, and expressed in
percentages. Values are the mean and SEM of six independent
experiments.
doi:10.1371/journal.pone.0018515.g005
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Similar data were obtained comparing genotypes1b and 2a with
genotypes 3a, 4d and 5a (Km between 100 mM and 200 mM). In
contrast, differences in Vmax were higher for genotype 1b vs. the
other genotypes, causing the significant variation (p-value,0.001)
in efficiency among the different genotypes (Table 2). Genotype 1b
showed the highest Vmax/Km ratio, especially when compared to
genotype 4d, which was almost 40-fold lower. In contrast, reaction
conditions to obtain maximum de novo RNA polymerase activity
were similar for all proteins (Fig. 4). Briefly, pH around 7, a final
NaCl concentration around 75 mM, and MnCl2 final concentra-
tion above 5 mM were necessary to achieve maximum activities
for all genotypes (Fig. 4). The highest activity shown by genotype
1b NS5B polymerase might be due to the presence of an Ile
residue at position 405. Recently, this position has been described
as a determinant for a more closed conformation, leading to a high
polymerase activity and high viral kinetics [44].
The interaction that occurs among viral RdRps is critical for
polymerase activity and virus proliferation [22,45–48]. Recently,
Kirkegaard and colleagues showed that the poliovirus RNA
polymerase is required to catalyze the polymerase reaction and
maintain the structure of the replication complex (RC) [49].
Indeed, the introduction of catalytically inactive polymerases into
infected cells did not disrupt the formation of RCs and allowed
RNA synthesis. However, the introduction of protein-protein
interaction mutants inactivated RCs [49].
HCV replicates its genetic material in RCs associated with the
endoplasmic reticulum membrane [50,51], and the ratio of RNA to
NS5B protein in these complexes has been calculated to be around
1 to 100 for positive strand RNA and 1 to 1000 for the replication
intermediate negative strand RNA [21]. These data suggest that not
all the NS5B proteins present in the HCV RC would necessarily be
acting as RdRp, and some of them could play a structural role.
Recent data highlight the relationship between oligomerization and
de novo activity [52]. We have shown the oligomerization of HCV
NS5B by a new FRET-based method that can detect and quantify
the degree of interaction between proteins under different
experimental conditions [23]. NS5B protein-protein interactions
are dependent on ionic strength [23,53]. Thus, the highest FRET
values were obtained at this lowest NaCl concentration tested
(10 mM) [23]. We have also demonstrated the lack of FRET signal
and oligomerization of a point mutant His502Ala [24]. Thus, by
evaluating HCV NS5B oligomerization in the presence of 10 mM
NaCl we should expect the highest FRET values allowing for the
detection of the greatest oligomerization defects. Our results
indicate oligomerization differences among genotypes, even at this
low NaCl concentration. The genotype 1b NS5BD21 protein had
the highest FRET ratio (Fig. 5B), whereas, NS5BD21-5a showed
values around 40% of the NS5BD21-1b. The low FRET ratio of
genotype 5a NS5B showed a high correlation with the correspond-
ing Hill coefficient result (Table 2). Furthermore, we have
performed FRET experiments under de novo reaction conditions
(66 mM NaCl and 5 mM MnCl2). Under these conditions, the
obtained results show a relationship with the Hill coefficient values
(compare Table 2 and Figure 5C). Also under these conditions,
genotype 5 showed the lowest FRET ratio.
It was intriguing to know if there is a relationship between the
polymerase sequence and cooperativity and oligomerization
Figure 6. NS5B electrostatic surface potential. A) Ribbon diagram within PYMOL 1.3 [33] showing the overall structure of HCV NS5B based on
the HC-J4 structure reported by Ja ¨ger and coworkers [59]. The symmetrical locations of F and T helices as well as the primary sequence
corresponding to aF helix for the genotypes used in this study are shown. B) Location of electrostatic surface potential for the putative ligand site in
the region corresponding to aF helix (Ser112-Asp129) of NS5B. C) Location of the electrostatic surface potential for the putative receptor site in the
region corresponding to aT (Pro495-Arg505. D) Ligand electrostatic surface potential for NS5B from genotypes G1b, G2a, G3a, G4d and G5a. In silico
mutagenesis were performed using Foldx [34] as described in Materials and Methods. The symbols . or = compare the intensity of electrostatic
surface potential on each phenotype. For panels B, C and D, the color coded electrostatic surface potential was drawn using the Adaptative Poisson-
Boltzmann equation as described in Materials and Methods [32].
doi:10.1371/journal.pone.0018515.g006
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this study is high (Fig. 1 and Table 1), only structural differences at
NS5B regions exposed to the solvent [54–59] and previously
related to NS5B-NS5B interactions were considered (Table 2 and
Fig. 5). According to the crystal structure 2ZKU.pdb, a-helixes C
(residues 62 to 78), F (residues 112 to 129), K (residues 231 to 242),
L (residues 247 to 260) and N (residues 329 to 346) are possible
sites of interaction with aT helix (His502). However, none of them
showed correlation between sequence changes and oligomeriza-
tion, except for the aF helix. The total number of changes in the
aF helix increased as oligomerization decreased (Fig. 6A).
Furthermore, the electronegative surface potential intensity clearly
decreased in parallel to a decrease in protein oligomerization
(Fig. 6D). Intriguingly, changes found in genotype 5 NS5B are in
the same position relative to the helix turn and facing the most
external part of the helix, leading to changes in the overall
electronegativity of the helix (Fig. 6B and 6D). The abundance of
Asp and Glu residues confers an electronegative surface potential
to the aF helix and makes this region a putative partner of protein-
protein interaction dominated by electrostatic interactions.
Simulation data showed that position Glu248 was important for
protein-protein interactions (Table 3 and Fig. 7), forming together
Figure 7. NS5B/NS5B docking model complexes showing the sites of protein-protein interaction and the amino acids involved in
ionic interactions. The side chain of amino acids that form ion pairs is highlighted with red color for acidic amino acids and blue color for basic
amino acids. Green and yellow colors for ribbons represent the putative ligand and receptor partners, respectively. Models 091, 004, 034, 042, 050,
and 061 are represented in panels A, B, C, D, E, and F, respectively. These models were obtained as described in Materials and Methods, and Table 3.
doi:10.1371/journal.pone.0018515.g007
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epitope involved in NS5B-NS5B interactions. The second partner
for these interactions may be the region of aT helix where His502
is located. This region has a high electropositive surface potential
intensity (see Fig. 6C) due to the number of basic residues present.
Some residues defined in Table 3 and Fig. 7 had been previously
related to oligomerization [22,24,55]. Fig. 1 shows that while the
aF helix has many mutations that alter their negative charge
density, the aT helix is very similar for all genotypes and mutations
are rare and very conservative. However, genotype 2 contains the
mutation His502Ser, and the cooperativity and oligomerization
values were high and almost similar to that of genotype 1. This
His502Ser mutation could be compensated with changes Pro247-
Glu, Arg250His, and Arg254His, all of them found in the
immediacy of Glu248. On the other hand, genotype 5 protein
contains mutation Glu128Gly, but in this case there are no
compensatory mutations in helix T. This might be the reason why
genotype 5 NS5B showed the lowest oligomerization values.
A number of crystal structures of the HCV polymerase (i.e.
1GX5, 1NHU, 1NHV, 1OS5, 1YVZ, 2BRL, 2D3U, 2D3Z,
Table 3. Representative parameters for docking models of NS5B.
Model name
(a)
Binding energy
(Kcal/mol)
(b)
Protein-Protein Ionic Interactions
in the NS5B(chain A)-NS5B(chain
B) complex
(c)
Protein-Protein Side Chain-Side
Chain Hydrogen Bonds in the
NS5B(chain A)-NS5B(chain B)
complex: donor-acceptor
(d)
Protein-Protein Main Chain-Side
Chain Hydrogen Bonds in the
NS5B(chain A)-NS5B(chain B)
complex: donor-acceptor
(d)
Model_091 211.89 475HIS(A)-129ASP(B) 476SER(A)-125ASP(B) 476SER(A)-128GLU(B)
498ARG(A)-248GLU(B) 476SER(A)-129ASP(B) 487SER(A)-117ASN(B)
501ARG(A)-128GLU(B) 498ARG(A)-248GLU(B) 533LYS(A)-128GLU(B)
502HIS(A)-248GLU(B) 502HIS(A)-248GLU(B) 248GLU(B)-498ARG(A)
505ARG(A)-248GLU(B) 248GLU(B)-502HIS(A) 251GLN(B)-531LYS(A)
Model_004 211.41 437GLU(A)-100LYS(B) 24ASN(A)-273ASN(B) 26LEU(A)-273ASN(B)
437GLU(A)-98LYS(B) 505ARG(A)-128GLU(B) 514GLN(A)-100LYS(B)
502HIS(A)-129ASP(B) 510ARG(A)-125ASP(B) 100LYS(B)-435ALA(A)
505ARG(A)-128GLU(B) 531LYS(A)-128GLU(B) 114LYS(B)-513SER(A)
510ARG(A)-125ASP(B) 273ASN(B)-24ASN(A) 125ASP(B)-505ARG(A)
531LYS(A)-128GLU(B)
Model_034 211.01 475HIS(A)-129ASP(B) 531LYS(A)-135ASP(B) 475HIS(A)-128GLU(B)
531LYS(A)-135ASP(B) 532THR(A)-121SER(B) 502HIS(A)-271GLY(B)
531LYS(A)-164ASP(B) 533LYS(A)-129ASP(B) 533LYS(A)-125ASP(B)
533LYS(A)-125ASP(B) 122VAL(B)-532THR(A)
533LYS(A)-129ASP(B) 125ASP(B)-531LYS(A)
259ARG(B)-531LYS(A)
273ASN(B)-498ARG(A)
Model_042 211.31 498ARG(A)-128GLU(B) 374HIS(A)-231ASN(B) 476SER(A)-234ARG(B)
498ARG(A)-129ASP(B) 231ASN(B)-374HIS(A) 502HIS(A)-128GLU(B)
502HIS(A)-128GLU(B) 65ARG(B)-380ARG(A)
72LYS(B)-376ALA(A)
234ARG(B)-477TYR(A)
Model_050 211.41 437GLU(A)-100LYS(B) 24ASN(A)-273ASN(B) 26LEU(A)-273ASN(B)
437GLU(A)-98LYS(B) 505ARG(A)-128GLU(B) 514GLN(A)-100LYS(B)
502HIS(A)-129ASP(B) 510ARG(A)-125ASP(B) 100LYS(B)-435ALA(A)
505ARG(A)-128GLU(B) 531LYS(A)-128GLU(B) 114LYS(B)-513SER(A)
510ARG(A)-125ASP(B) 273ASN(B)-24ASN(A) 125ASP(B)-505ARG(A)
531LYS(A)-128GLU(B)
Model_061 211.20 498ARG(A)-128GLU(B) 374HIS(A)-231ASN(B) 476SER(A)-234ARG(B)
498ARG(A)-129ASP(B) 231ASN(B)-374HIS(A) 502HIS(A)-128GLU(B)
502HIS(A)-128GLU(B) 65ARG(B)-380ARG(A)
72LYS(B)-376ALA(A)
234ARG(B)-477TYR(A)
(a)The models have been generated by the server GRAMM-X using 2zku.pdb as a template (35).
(b)Calculated with FoldX software package (34).
(c)The ionic interaction as obtained from Protein Interaction Calculator (36), showing the positions of the residue pairs in NS5B(chain A)-NS5B(chain B) docked
complexes.
(d)Obtained from Protein Interaction Calculator (36).
doi:10.1371/journal.pone.0018515.t003
HCV RdRP De Novo Activity and Oligomerization
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e185152D41, 2DXS, 2GIR, 2HAI, 2HWH, 2HWI, 2I1R, 2JC0, 2O5D,
2WCX, 2WHO, 3CJ0, 3CJ2, 3CJ3, 3CJ4, 3CJ5, 3FRZ and
3HVO), show that the aT helix is close to a site of interaction for
non-nucleoside inhibitors. When comparing the secondary
structure of various crystals of NS5B/NNI complexes the overall
structure clearly remains relatively unchanged upon inhibitor
binding, except for positions in the region Pro495-Arg505 [25].
Biswal and coworkers [25] explained the mechanism of action of
thiophene-based inhibitors in two directions: first, the structural
shifts of aT helix affect the integrity of the GTP binding site,
resulting in reduced affinity for GTP and contributing to the
formation of an RNA polymerase state incapable of carrying out a
polymerization cycle. Secondly, the NS5B may need to oligomer-
ize in order to function. His502 is one of the critical residues
involved in homomeric interaction levels and mutants His502Glu
and His502Ala abolish the enzymatic activity [24]. The position of
His502 in the NNI bound-state is greatly perturbed suggesting that
non-nucleoside inhibitors could have profound effect on the
oligomerization process [25]. Additionally, it seems clear that
variations in the negative charge density of the aF helix among
different genotypes should also help to explain the variations in the
degree of oligomerization. Ongoing work should define the role
played by these two NS5B regions in the oligomerization process.
Results in this study have not allowed us to establish a clear
relationship between activity and oligomerization. Site-directed
mutagenesis of these two regions will be very useful to understand
the role of oligomerization, if any, in de novo initiation, primer
extension and template switching activities. Such experiments will
also help to establish a better understanding of the differences
observed in FRET ratios when comparing different reaction
conditions (Figures 5B and 5C).
The efficacy of current HCV treatment regimens and those in
current clinical trials is dependent on the HCV genotype.
Understanding functional and structural differences among
HCV genotypes is crucial for the design of new therapies.
Hampering the interaction among NS5B polymerases has been
proposed as a mechanism of action for drugs under development
[23–26]. Our study provides, for the first time, evidence of the de
novo RNA-polymerase activity and oligomerization of NS5B from
genotypes different to genotypes 1 and 2 and propose candidate
regions involved in NS5B-NS5B interactions. A better under-
standing of the replication process and how this is affected by
genotypic differences may allow the development of effective
treatments against all the HCV genotypes.
Supporting Information
Figure S1 Electro-mobility shift assay. A) Native poly-
acrylamide gel showing the RNA free probe (lane 1) as well as
retarding products for genotype 1 (lanes 2 and 3), genotype 2 (lanes
4 and 5), genotype 3 (lanes 6 and 7), genotype 4 (lanes 8 and 9),
and genotype 5 (lanes 10 and 11). The NS5B concentration was
fixed to0.6 mM(lanes2,4,6,8,and10)and 1.8 mM (lanes3,5,7,9,
and 11). B) Representation of the ratio of protein-bound to RNA
free probe (in percentage). For each genotype and each protein
concentration used (0.6 and 1.8 mM) the percentage of the free
RNA probe (in white) and the protein-bound RNA probe (in black)
are represented. C) Comparison between Vmax/Km data from
Table 2 and those data normalized using the ratios obtained from
the electro-mobility shift assay.
(PPT)
Figure S2 Hill coefficient data. Panels A, B, C, D, and E
represent the kinetic data for NS5B from genotypes 1, 2, 3, 4, and
5, respectively. The r2 values are shown for all graphics. The best
fit of the experimental data was to a sigmoidal curve, as described
in Materials and Methods, except for genotype 5, which did not fit
to a sigmoidal curve and instead produced a better fit to a linear
curve.
(PPT)
Figure S3 Activity of NS5B-fused proteins. LE19 oligonu-
cleotide was used as the template and de novo polymerase activity
was analyzed in polymerase buffer (MOPS 20 mM, NaCl 66 mM,
MnCl2 5 mM) in the presence of 125 mM NTPs, and 0.5 mCi of
a[
32P]GTP (3000 Ci/mmol, PerkinElmer). Reactions were initi-
ated by the addition of 600 nM purified NS5B and incubated at
25uC. After one hour of incubation reactions were stopped and
products were resolved in a polyacrylamide gel and visualized by
phosphorimaging.
(PPT)
Table S1 Primers used in the study.
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